Actively Recruiting

Age: 18Years - 70Years
All Genders
NCT06746155

Predictors of Relapse in Major Depressive Disorder

Led by Abraham Nunes · Updated on 2024-12-24

252

Participants Needed

1

Research Sites

259 weeks

Total Duration

On this page

Sponsors

A

Abraham Nunes

Lead Sponsor

M

McMaster University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Major depressive disorder (MDD) is a common condition involving recurring periods of depression. One of the major challenges faced by people with MDD is that the episodes of depression tend to recur even after they are successfully treated. Currently, it is hard to predict when a depressive episode will recur. Being able to forecast this would help healthcare providers monitor patients and prevent relapse. The purpose of this study is to monitor features such as clinical symptoms, physical activity, sleep patterns, cognitive functioning and brain activity to help us understand how relapse happens and the mechanisms that cause it. From these different types of data, investigators will build a model that tells us who is more likely to experience a relapse and when the relapse is likely to occur. This study will be a significant step forward in understanding and managing MDD. Investigator will create a practical tool that will allow healthcare providers to monitor patients more effectively. By identifying early signs of relapse, investigators may be able to intervene promptly to prevent depressive episodes. Finally, our research will help understand the factors that underlie relapse in MDD, which will encourage the development of novel treatment approaches.

CONDITIONS

Official Title

Predictors of Relapse in Major Depressive Disorder

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Outpatients 18 to 70 years of age
  • Meet DSM-V criteria for Major Depressive Disorder as determined by SCID-5
  • Currently responding or responded to treatment for a major depressive episode, or in remission without medication
  • Montgomery-Asberg Depression Rating Scale (MADRS) total score of 14 or less
  • Willing and able to complete self-reported assessments with sufficient English fluency
  • Willing to wear a wrist-worn activity device for the study duration
Not Eligible

You will not qualify if you...

  • Diagnosis of Bipolar I or Bipolar-II disorder, schizophrenia, or schizoaffective disorder
  • Elevated risk of suicide as determined by clinical evaluation
  • Major neurological disorders or significant head injury with loss of consciousness over 24 hours, Glasgow Coma Scale less than 9, or post-traumatic amnesia over 24 hours
  • Any unstable medical condition
  • Any condition that could interfere with study assessments as judged by the researcher
  • Employment by the researcher, active involvement in this study or related research, or being a relative of a study employee or the researcher

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Nova Scotia Health

Halifax, Nova Scotia, Canada

Actively Recruiting

Loading map...

Research Team

V

Vanessa Pardo, BA (Hons)

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here